Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis
Sohan Deshpande,A. D. I. van Asselt,Florian Tomini,Nigel Armstrong,A Allen,Caro Noake,Khalid S. Khan,Johan L. Severens,Jos Kleijnen,Marie Westwood +9 more
TLDR
Fetal fibronectin testing has moderate accuracy for predicting preterm birth (PTB) in symptomatic women and there is a need for high-quality adequately powered trials using appropriate study designs to confirm the findings presented.Abstract:
BACKGROUND: Premature birth is defined as birth of before 37 completed weeks' gestation. Not all pregnant women showing symptoms of preterm labour will go on to deliver before 37 weeks' gestation. Hence, addition of fetal fibronectin (fFN) testing to the diagnostic workup of women with suspected preterm labour may help to identify those women who do not require active management, and thus avoid unnecessary interventions, hospitalisations and associated costs. OBJECTIVE: To assess the clinical effectiveness and cost-effectiveness of rapid fFN testing in predicting preterm birth (PTB) in symptomatic women. DATA SOURCES: Bibliographic databases (including EMBASE, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials) were searched from 2000 to September/November 2011. Trial registers were also searched. REVIEW METHODS: Systematic review methods followed published guidance; we assessed clinical effectiveness and updated a previous systematic review of test accuracy. Risk of bias was assessed using the Cochrane tool (randomised controlled trials; RCTs) and a modification of QUADAS-2 (diagnostic test accuracy studies; DTAs). Summary risk ratios or weighted mean difference were calculated using random-effects models. Summary sensitivity and specificity used a bivariate summary receiver operating characteristic model. Heterogeneity was investigated using subgroup and sensitivity analyses. Health economic analysis focused on cost consequences. The time horizon was hospital admission for observation. A main structural assumption was that, compared with usual care, fFN testing doesn't increase adverse events or negative pregnancy outcomes. RESULTS: Five RCTs and 15 new DTAs were identified. No RCT reported significant effects of fFN testing on maternal or neonatal outcomes. One study reported a subgroup analysis of women with negative fFN test observed > 6 hours, which showed a reduction in length of hospital stay where results were known to clinicians. Combining data from new studies and the previous systematic review, the pooled estimates of sensitivity and specificity were: 76.7% and 82.7% for delivery within 7-10 days of testing; 69.1% and 84.4% for delivery < 34 weeks' gestation; and 60.8% and 82.3% for delivery < 37 weeks' gestation. Estimates were similar across all subgroups sensitivity analyses. The base-case cost analysis resulted in a cost saving of £23.87 for fFN testing compared with usual care. The fFN testing was cost-neutral at an approximate cost of £45. Probabilistic sensitivity analysis gave an incremental cost (saving) of -£25.59 (97.5% confidence interval -£304.96 to £240.06), indicating substantial uncertainty. Sensitivity analyses indicated that admission rate had the largest impact on results. CONCLUSIONS: Fetal fibronectin testing has moderate accuracy for predicting PTB. The main potential role is likely to be reducing health-care resource usage by identifying women not requiring intervention. Evidence from RCTs suggests that fFN does not increase adverse outcomes and may reduce resource use. The base-case analysis showed a modest cost difference in favour of fFN testing, which is largely dependent on whether or not fFN testing reduces hospital admission. Currently, there are no high-quality studies and the existing trials were generally underpowered. Hence, there is a need for high-quality adequately powered trials using appropriate study designs to confirm the findings presented. STUDY REGISTRATION: PROSPERO 2011:CRD42011001468. Available from www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42011001468. FUNDING: The National Institute for Health Research Health Technology Assessment programme.read more
Citations
More filters
Journal ArticleDOI
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata,Ann-Lii Cheng,Norihiro Kokudo,Masatoshi Kudo,Jeong Min Lee,Jidong Jia,Ryosuke Tateishi,Kwang Hyub Han,Yoghesh K. Chawla,Shuichiro Shiina,Wasim Jafri,Diana A. Payawal,Takamasa Ohki,Sadahisa Ogasawara,Pei-Jer Chen,Cosmas Rinaldi Adithya Lesmana,Laurentius A. Lesmana,Rino Alvani Gani,Shuntaro Obi,A. Kadir Dokmeci,Shiv Kumar Sarin +20 more
TL;DR: The latest guidelines for the treatment of HCC recommend evidence-based management and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.
Journal ArticleDOI
International consensus on (ICON) anaphylaxis
F. Estelle R. Simons,Ledit R.F. Ardusso,M. Beatrice Bilò,Victoria Cardona,Motohiro Ebisawa,Yehia El-Gamal,Phil Lieberman,Richard F. Lockey,Antonella Muraro,Graham Roberts,Mario Sánchez-Borges,Aziz Sheikh,Lynette Pei-Chi Shek,Dana Wallace,Margitta Worm +14 more
TL;DR: These guidelines concur about prompt initial treatment with intramuscular injection of epinephrine (adrenaline) in the mid-outer thigh, positioning the patient supine, calling for help, and when indicated, providing supplemental oxygen, intravenous fluid resuscitation and cardiopulmonary resuscitation.
Journal ArticleDOI
Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme.
Stephen J Walters,Inês Bonacho dos Anjos Henriques-Cadby,Oscar Bortolami,Laura Flight,Daniel Hind,Richard Jacques,Christopher Knox,Ben Nadin,Joanne C. Rothwell,Michael Surtees,Steven A. Julious +10 more
TL;DR: There is considerable variation in the consent, recruitment and retention rates in publicly funded RCTs and investigators should bear this in mind at the planning stage of their study and not be overly optimistic about their recruitment projections.
References
More filters
Journal ArticleDOI
Meta-Analysis in Clinical Trials*
TL;DR: This paper examines eight published reviews each reporting results from several related trials in order to evaluate the efficacy of a certain treatment for a specified medical condition and suggests a simple noniterative procedure for characterizing the distribution of treatment effects in a series of studies.
Book
Cochrane Handbook for Systematic Reviews of Interventions
Julian P T Higgins,Sally Green +1 more
TL;DR: The Cochrane Handbook for Systematic Reviews of Interventions is the official document that describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of healthcare interventions.
Journal ArticleDOI
The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews
TL;DR: In this article, an evidence-based quality assessment tool called QUADAS was proposed to assess the quality of primary studies of diagnostic accuracy, based on the results of three previously conducted reviews of the diagnostic literature.
Related Papers (5)
Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS.
Michel Claudon,Christoph F. Dietrich,Byung Ihn Choi,David O. Cosgrove,Masatoshi Kudo,Christian Pállson Nolsøe,Fabio Piscaglia,Stephanie R. Wilson,Richard G. Barr,Maria Cristina Chammas,Nitin Chaubal,Min-hua Chen,Dirk-André Clevert,Jean Michel Correas,Hong Ding,Flemming Forsberg,J. Brian Fowlkes,Robert N Gibson,Barry B. Goldberg,Nathalie Lassau,Edward Leen,Robert F. Mattrey,Fuminori Moriyasu,Luigi Solbiati,Hans Peter Weskott,Hui-Xiong Xu +25 more
The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations.
Fabio Piscaglia,Luigi Bolondi +1 more
Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver - Update 2012
Michel Claudon,Christoph F. Dietrich,Byung Ihn Choi,David O. Cosgrove,Masatoshi Kudo,Christian Pállson Nolsøe,Fabio Piscaglia,Stephanie R. Wilson,Richard G. Barr,Maria Cristina Chammas,Nitin Chaubal,Min-hua Chen,Dirk A. Clevert,J. M. Correas,Hong Ding,Flemming Forsberg,J. B. Fowlkes,Robert N Gibson,Barry B. Goldberg,Nathalie Lassau,Edward Leen,Robert F. Mattrey,Fuminori Moriyasu,Luigi Solbiati,H. P. Weskott,Hui-Xiong Xu +25 more